BNP Paribas Financial Markets Decreases Stock Position in Lantheus Holdings, Inc. $LNTH

BNP Paribas Financial Markets cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 53.5% in the fourth quarter, HoldingsChannel reports. The firm owned 306,723 shares of the medical equipment provider’s stock after selling 352,581 shares during the quarter. BNP Paribas Financial Markets’ holdings in Lantheus were worth $20,412,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of LNTH. Blue Trust Inc. lifted its holdings in Lantheus by 30.3% during the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock worth $66,000 after buying an additional 230 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in Lantheus by 71.4% during the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 275 shares during the last quarter. Resona Asset Management Co. Ltd. lifted its holdings in Lantheus by 35.7% during the 4th quarter. Resona Asset Management Co. Ltd. now owns 1,109 shares of the medical equipment provider’s stock worth $75,000 after buying an additional 292 shares during the last quarter. Verdence Capital Advisors LLC lifted its holdings in Lantheus by 3.8% during the 4th quarter. Verdence Capital Advisors LLC now owns 8,455 shares of the medical equipment provider’s stock worth $563,000 after buying an additional 310 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in Lantheus by 2.4% during the 4th quarter. ProShare Advisors LLC now owns 14,911 shares of the medical equipment provider’s stock worth $992,000 after buying an additional 355 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LNTH has been the subject of a number of recent analyst reports. B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a report on Friday, May 1st. William Blair reissued an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Stock Down 1.8%

Lantheus stock opened at $100.98 on Friday. The company has a market capitalization of $6.57 billion, a P/E ratio of 24.33 and a beta of -0.03. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $104.00. The stock has a 50-day simple moving average of $88.01 and a 200-day simple moving average of $74.96. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. The firm had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts expect that Lantheus Holdings, Inc. will post 4.42 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.